Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY – Get Free Report) shares hit a new 52-week high during trading on Thursday . The stock traded as high as $16.34 and last traded at $15.69, with a volume of 39734 shares traded. The stock had previously closed at $15.53.
Chugai Pharmaceutical Stock Performance
The company has a market cap of $53.56 billion, a PE ratio of 22.30 and a beta of 0.60. The firm’s 50 day moving average is $15.17 and its 200-day moving average is $14.55.
Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $0.16 earnings per share (EPS) for the quarter. The business had revenue of $1.78 billion during the quarter. Chugai Pharmaceutical had a net margin of 26.35% and a return on equity of 22.11%. On average, analysts predict that Chugai Pharmaceutical Co., Ltd. will post 0.66 EPS for the current year.
Chugai Pharmaceutical Company Profile
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
- Five stocks we like better than Chugai Pharmaceutical
- Insider Trading – What You Need to Know
- MarketBeat Week in Review – 11/13 – 11/17
- Investing in Commodities: What Are They? How to Invest in Them
- 3 large caps with red hot RSIs with upside
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Johnson Controls International: Nothing but upside for investors
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.